• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A leading pure play vaccine company.

2015 Annual Business Report

— December 1, 2016

Leading Healthcare Investor MVM Life Science Partners Acquires 7.5% Shareholding in Valneva

Read more

— Stock information

@valnevase




















-
— July 25, 2016
Valneva Announces Successful Completion of Phase II for C. Diff Vaccine Candidate

Read more

DEVELOPING A VACCINE FOR LYME DISEASE
Key Opinion Leader Lunch

December 12, 2016
Invitation
Webcast

JAPANESE
ENCEPHALITIS
AND
CHOLERA



learn more
play video Valneva's CEO Thomas Lingelbach
comments on Group Strategy

– Upcoming conferences and fairs



Key Opinion Leader Lunch 
Developing a Vaccine for Lyme Disease
December 12, 2016

Invitation

Oddo Forum
Lyon, France
January 5-6, 2017

J.P. Morgan 35th Annual Healthcare Conference
San Francisco, US
January 9-12, 2017

Please update your browser...